Bausch Health Companies Inc.
BHC
NYSE·Healthcare·Drug Manufacturers - Specialty & Generic·Mkt cap $2.5B
$6.56
▼ -2.96%
P/E
-2.52
Mkt Cap
$2.5B
52-Wk Range
$4.33–$8.00
52-Week Range
$4.33 - $8.00
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 10.5% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Strong iconic brand portfolio including the globally recognized Bausch + Lomb name in vision care
- Diversified product pipeline across high-demand therapeutic areas with recurring patient needs
- Established international distribution network across Canada, Europe, Asia, and emerging markets
- Integrated manufacturing and marketing capabilities providing operational efficiency and cost advantages
Bear Case
1 risk
- Low volatility (beta 0.4).
Growth
Turning profitable
Rising global demand for eye health and vision care solutions driven by aging populations and digital device usage
Value
Deep value opportunity - significant discount to Large Cap Pharma peers
Momentum
Hot
+28.4% over 3m
Quality
Excellent
Strong fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying BHC right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Oct 28, 2026
JUL 29, 2026
Reported EPS of $1.26 vs $0.96 consensus (+31.3% surprise). Revenue of $2.8B vs $2.6B expected (+8.7%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+31.3%
Revenue trend · last 8Q
—
—
—
+7%
+6%
+11%
+11%
+10%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$1.8B
$1.8B
$1.6B
$1.9B
$1.9B
$2.0B
$1.8B
$2.8B
Margins · last 8Q
Gross
99.3%
Operating
26.2%
Profit
9.1%
Wall Street consensus
1 analyst · 0% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
0%
Hold
100%
Sell
0%
Median Price Target
—
Latest: RBC Capital · Apr 27, 2026
vs Industry
How BHC stacks vs Drug Manufacturers - Specialty & Generic
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related